Charles Bennett to Disease Progression
This is a "connection" page, showing publications Charles Bennett has written about Disease Progression.
Connection Strength
0.185
-
HIV and AIDS: an overview. Nurs Stand. 2001 Feb 28-Mar 6; 15(24):45-52; quiz 54-5.
Score: 0.035
-
Quality of life in metastatic prostate cancer among men of lower socioeconomic status: feasibility and criterion related validity of 3 measures. J Urol. 1998 Nov; 160(5):1765-9.
Score: 0.030
-
Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer. 1996 May 01; 77(9):1854-61.
Score: 0.025
-
The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int. 2013 Sep; 112(5):548-60.
Score: 0.021
-
American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010 Nov 18; 116(20):4045-59.
Score: 0.017
-
American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010 Nov 20; 28(33):4996-5010.
Score: 0.017
-
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr 20; 25(12):1596-605.
Score: 0.013
-
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004 Jul 15; 22(14):2927-41.
Score: 0.011
-
Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000 Apr 04; 132(7):566-77.
Score: 0.008
-
QOL and outcomes research in prostate cancer patients with low socioeconomic status. Oncology (Williston Park). 1999 Jun; 13(6):823-32; discussion 835-8.
Score: 0.008